1000278215.jpg
Find the disease
analyse_media
Reading File
Chronic Lymphocytic Leukemia (CLL)
This is a peripheral blood smear showing Chronic Lymphocytic Leukemia (CLL).
Key Findings in the Image
| Feature | What is Seen |
|---|---|
| Dominant cell type | Abundant small, mature-appearing lymphocytes with scant cytoplasm |
| Nuclear chromatin | Dense, coarsely clumped ("soccer-ball" / "cracked mud" pattern) |
| Nucleoli | Absent or inconspicuous |
| N:C ratio | High - very thin rim of pale blue cytoplasm |
| Smudge cells | Present (the purple fibrous streaks) - fragile neoplastic lymphocytes ruptured during smear preparation; this is the hallmark of CLL |
| RBCs | Normocytic, normochromic (normal) |
Diagnosis: Chronic Lymphocytic Leukemia (CLL)
CLL is the most common adult leukemia in the Western world. It is a clonal proliferation of mature-appearing but functionally incompetent B lymphocytes (CD5+, CD19+, CD23+).
Why CLL and not other lymphocytoses?
- The monotonous, uniform population of small lymphocytes
- Dense clumped chromatin (vs. large cells of ALL or blasts of AML)
- Smudge/basket cells are pathognomonic - these result from the increased fragility of CLL cells
Diagnostic Criteria (IwCll 2018)
- Peripheral blood lymphocyte count ≥5 × 10⁹/L of clonal B cells
- Confirmed by flow cytometry: CD5+, CD19+, CD23+, weak surface Ig, FMC7-
- Bone marrow biopsy not required for diagnosis
Clinical Pearl
The smudge (Gumprecht shadow) cell is the single most recognizable feature of CLL on a blood smear. Adding albumin to the smear can reduce smudge cell formation, confirming their presence is artefactual fragility of neoplastic lymphocytes.
Why LAP score decrease in CML
The LAP (Leukocyte Alkaline Phosphatase) score is low or near zero in CML because the neoplastic neutrophils, driven by the BCR-ABL oncoprotein, are functionally immature and enzymatically deficient despite appearing morphologically mature. This is a key distinguishing feature from reactive leukocytosis.
Searching sources...
Finding Sources
Finding Sources
Reading File
Finding Sources
Here is a detailed explanation of why the LAP score is low in CML, confirmed by Harrison's Principles of Internal Medicine 22E which notes that "biochemical abnormalities include a low leukocyte alkaline phosphatase score" as a key CML finding:
Why is the LAP Score Low in CML?
What is the LAP Score?
Leukocyte Alkaline Phosphatase (LAP) is an enzyme found in the granules of mature, segmented neutrophils and band forms. A LAP score is calculated by scoring 100 neutrophils (0-4+ staining intensity per cell), giving a maximum of 400. Normal range: 20-100.
In CML, the LAP score is characteristically low (0-20), often near zero.
The Core Reason: BCR-ABL Drives Functional Immaturity
The low LAP score in CML comes down to one fundamental mechanism:
| Normal Neutrophil | CML Neutrophil |
|---|---|
| Fully mature, functionally competent | Morphologically mature but functionally abnormal |
| High LAP enzyme in granules | Deficient or absent LAP |
| Produced by normal hematopoiesis | Produced by the BCR-ABL oncoprotein-driven clone |
Step-by-Step Mechanism
-
BCR-ABL Translocation (Philadelphia Chromosome t(9;22))
- The BCR-ABL fusion gene encodes a constitutively active tyrosine kinase
- This drives uncontrolled proliferation of the myeloid clone
-
Accelerated Proliferation = Maturation Arrest in Granule Formation
- CML neutrophils are pushed through maturation too rapidly
- They do not spend adequate time in the myelocyte/metamyelocyte stage where secondary (specific) granules containing LAP are synthesized
- Result: mature-looking cells with granule enzyme deficiency
-
Transcriptional Downregulation of LAP (ALP/ALPL gene)
- BCR-ABL signaling suppresses expression of alkaline phosphatase gene in granulocytes
- The enzyme is simply not made at normal levels, regardless of cell maturity
- This is a direct molecular consequence of the neoplastic transformation
-
Clonal Expansion of an Abnormal Progenitor
- Normal mature neutrophils in circulation are replaced by the CML clone
- The neoplastic clone lacks the full enzymatic machinery of healthy neutrophils
Clinical Significance: LAP as a Diagnostic Tool
| Condition | LAP Score |
|---|---|
| CML | Very low (0-20) |
| Leukemoid reaction (infection, severe stress) | Very high (>200) |
| Polycythemia vera | High |
| Pregnancy / oral contraceptives | Elevated |
| PNH (Paroxysmal Nocturnal Hemoglobinuria) | Low |
| Normal | 20-100 |
This contrast between CML (low LAP) and a leukemoid reaction (high LAP) is the most important clinical use of the LAP score - it helps differentiate the two conditions that both present with a massively elevated WBC count.
Simple Memory Hook
"In CML, the cells look like neutrophils but don't work like neutrophils - they lack the enzyme that normal mature cells have."
The BCR-ABL tyrosine kinase essentially produces a factory of dysfunctional cells - they mature morphologically but are enzymatically and functionally crippled, and LAP deficiency is one measurable expression of that dysfunction.
That was ALl. You told Wrong
You're right to push back. Let me look this up properly before giving you a corrected answer.
Researching further...
Finding Sources
Searching the Web
why is LAP score decreased in CML mechanism BCR-ABL alkaline phosphatase neutrophil
Thank you for the correction. The research reveals the actual mechanism is more nuanced and different from what I stated. Here is the corrected, evidence-based explanation:
Why LAP Score is Low in CML - The Correct Mechanism
The True Cause: LAP mRNA Deficiency + Premature Release from Bone Marrow
My previous answer incorrectly attributed the low LAP to "accelerated proliferation causing granule formation defects." The actual mechanism, according to research (PMID 10233380), is:
1. LAP is a Marker of Terminal Differentiation Only
In normal granulopoiesis, LAP is not expressed throughout maturation - it is only acquired at the very last stage of neutrophil maturation: the terminally differentiated, post-mitotic, CD11b-bright/CD16-bright neutrophil stage.
Think of LAP as the "final finishing touch" applied only to fully mature, ready-for-release neutrophils.
2. CML Neutrophils are Released Prematurely from Bone Marrow
The BCR-ABL oncoprotein causes:
- Massively accelerated proliferation of the myeloid clone
- Precocious (premature) release of granulocytes from bone marrow into the bloodstream before they complete terminal differentiation
- These cells look morphologically mature but have not yet acquired LAP at their final maturation step
This is the primary mechanism - the cells leave the marrow too early, skipping the final step where LAP mRNA is expressed and LAP protein is synthesized.
3. LAP mRNA Deficiency - Not Directly BCR-ABL Kinase Activity
This is the key point that corrects my earlier answer:
- CML neutrophils have a deficiency of LAP mRNA - the gene is simply not transcribed adequately
- Crucially, research showed that inhibiting BCR-ABL p210 tyrosine kinase activity (with genistein or early kinase inhibitors) did NOT restore LAP mRNA expression
- This means the low LAP is not a direct enzymatic consequence of BCR-ABL kinase activity itself
- Instead, it is a consequence of the abnormal, premature maturation pathway that BCR-ABL forces on granulocyte precursors
4. The Role of G-CSF
- G-CSF is a potent regulator of LAP mRNA expression
- In normal neutrophils, G-CSF strongly upregulates LAP
- Even in CML neutrophils, G-CSF can induce LAP surface expression
- This further supports the idea that the defect is one of missing maturation stimulus, not an irreversible genetic incapacity to make the enzyme (PMID 2239924 - CML neutrophils in pleural effusion exposed to pleural fluid stimuli turned LAP-positive!)
Summary in One Sentence
CML neutrophils are released prematurely from the bone marrow by BCR-ABL-driven proliferative pressure before they complete terminal differentiation, resulting in LAP mRNA deficiency and absent LAP enzyme activity - this defect is not a direct effect of BCR-ABL kinase activity itself.
What Happens When CML is Treated?
Consistent with this mechanism - when patients achieve hematologic remission with imatinib, LAP scores return to normal levels, because normal terminal differentiation resumes (UHOD 2010 study).
| State | LAP Score |
|---|---|
| Active CML | Very low (0-20) |
| CML in remission (post-imatinib) | Normalizes |
| Leukemoid reaction | Very high (>200) |
I apologize for the inaccurate initial explanation.
This is a shared conversation. Sign in to Orris to start your own chat.